Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12652354 | 0.83 | LMNA (0.43) | SIGMAR1SLC6A4 | |
| SCHEMBL24464886 | 0.83 | LMNA (0.43) | SIGMAR1SLC6A4 | |
| SCHEMBL17104329 | 0.81 | LMNA (0.42) | SIGMAR1SLC6A4 | |
| SCHEMBL17104304 | 0.81 | LMNA (0.42) | SIGMAR1SLC6A4 | |
| SCHEMBL17104336 | 0.81 | LMNA (0.42) | SIGMAR1SLC6A4 | |
| SCHEMBL17104298 | 0.81 | LMNA (0.42) | SIGMAR1SLC6A4 | |
| SCHEMBL17104334 | 0.81 | LMNA (0.42) | SIGMAR1SLC6A4 | |
| SCHEMBL17104299 | 0.81 | LMNA (0.42) | SIGMAR1SLC6A4 | |
| SCHEMBL13660465 | 0.79 | — | — | |
| SCHEMBL4155536 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10833186-B2 | Gallium nitride epitaxial structures for power devices | QROMIS, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200190136-A1 | METHODS FOR GENERATING SMALL MOLECULE DEGRADERS AND DIMERIZERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-8450522-B2 | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2013-05-28 | — | — | US | disclosed |